Difference between revisions of "Team:UCL/Dental hygiene"

Line 66: Line 66:
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box"><h2> <center> Our approach: a bacteriocin producing device </center> </h2> <br>
 
                     <div class="col-md-8 col-md-offset-2 ess-template-general animate-box"><h2> <center> Our approach: a bacteriocin producing device </center> </h2> <br>
 
                       <h4> A decrease in biofilm formation caused by interference with the viability of certain bacterial species presents an approach towards limiting cariogenesis. Our team designed a locus capable of producing and exporting a mature form of an antimicrobial peptide known as mutacin III, first identified in Streptococcus mutans UA787 isolated from a caries-active white female patient in the late 1980s (4). Mutacin III is effective against a wide range of Gram-positive bacteria implicated in dental caries, e.g. other strains of Streptococcus mutans and Actinomyces naeslundii, while Gram-negative bacteria are resistant to inhibition (5).<br>
 
                       <h4> A decrease in biofilm formation caused by interference with the viability of certain bacterial species presents an approach towards limiting cariogenesis. Our team designed a locus capable of producing and exporting a mature form of an antimicrobial peptide known as mutacin III, first identified in Streptococcus mutans UA787 isolated from a caries-active white female patient in the late 1980s (4). Mutacin III is effective against a wide range of Gram-positive bacteria implicated in dental caries, e.g. other strains of Streptococcus mutans and Actinomyces naeslundii, while Gram-negative bacteria are resistant to inhibition (5).<br>
  </h4><br><br>
+
  </h4>
<h4> The information on the design of the mutacin III biosynthetic device can be found ''here'' </h4>
+
  
 
<br><br>
 
<br><br>
 +
 
<h4> In one investigation of the activity of mutacin-related lantibiotic gallidermin it became clear that lantibiotics are more effective in preventing biofilm formation rather than in exterminating microorganisms already embedded in biofilms (6). To reflect this, our device could be used to transform E. coli cells and employed as an anti-cariogenic strategy in replacement therapy (Fig. 1). Such a novel bacterial strain would demonstrate features of a successful effector strain as it would not cause disease by itself and because it could displace the host pathogenic bacteria. Importantly, there are very few existing examples of lantibiotic resistance compared with antibiotics and only one mechanism of resistance to mutacin III, known as CprRK in Clostridium difficile, has been established (7). Moreover, the fact that a closely related lantibiotic nisin has been shown to exhibit low in vivo toxicity levels (8) and has been widely used as food preservative from as early as mid 1940s (9) further encourages the prospect of considering the employment of mutacin III as an anti-cariogenic agent. </h4>
 
<h4> In one investigation of the activity of mutacin-related lantibiotic gallidermin it became clear that lantibiotics are more effective in preventing biofilm formation rather than in exterminating microorganisms already embedded in biofilms (6). To reflect this, our device could be used to transform E. coli cells and employed as an anti-cariogenic strategy in replacement therapy (Fig. 1). Such a novel bacterial strain would demonstrate features of a successful effector strain as it would not cause disease by itself and because it could displace the host pathogenic bacteria. Importantly, there are very few existing examples of lantibiotic resistance compared with antibiotics and only one mechanism of resistance to mutacin III, known as CprRK in Clostridium difficile, has been established (7). Moreover, the fact that a closely related lantibiotic nisin has been shown to exhibit low in vivo toxicity levels (8) and has been widely used as food preservative from as early as mid 1940s (9) further encourages the prospect of considering the employment of mutacin III as an anti-cariogenic agent. </h4>
 
   
 
   
Line 76: Line 76:
 
<p> <center> Fig. 1. Simplified representation of the application of the mutacin III biosynthetic device in replacement therapy </center> </p>
 
<p> <center> Fig. 1. Simplified representation of the application of the mutacin III biosynthetic device in replacement therapy </center> </p>
 
<br>
 
<br>
 +
<br>
 +
<h4> The information on the design of the mutacin III biosynthetic device can be found ''here'' </h4>
  
 +
<br><br>
 
</div>
 
</div>
 
                 </div>
 
                 </div>

Revision as of 13:54, 18 October 2016

<!DOCTYPE html>

UCL iGEM 2016 | BioSynthAge

Healthy teeth, healthy ageing

Explore how we are re-designing the oral microbiome
to prevent tooth decay



Healthy heart, healthy ageing

See how we are re-designing the gut microbiome to reduce blood pressure as way of reducing the chance of age-related complications with the heart.

WHY TEETH?

The deterioration of oral health in the elderly is accompanied by an increased prevalence of caries and periodontal disease which are risk factors for some systemic diseases and nutrition problems (1), whereas the status of dental hygiene has been recognized as an important determinant of psychological well-being and its aggravation has been associated with an elevated incidence of depressive symptoms (2). In our project, we designed a biosynthetic device to serve as an alternative in preventative dental care for the elderly.

The problem: Biofilm formation and cariogenesis


The oral cavity is inhabited by a wide range of interacting communities of metabolically and structurally organized microorganisms which synthesize an extracellular polysaccharide matrix (EPS) enabling them to adhere to the surface of the teeth and assemble in matrix-embedded biofilms. Progressing biofilm accumulation puts the bacteria under increasing metabolic stress which leads to localized metabolite and acid accumulation and a shift in the dynamic homeostasis towards acid-tolerating species such as Gram-positive Streptococcus mutans (3). A resultant decrease in pH causes tooth demineralization and constitutes a mechanism of dental caries.



Our approach: a bacteriocin producing device


A decrease in biofilm formation caused by interference with the viability of certain bacterial species presents an approach towards limiting cariogenesis. Our team designed a locus capable of producing and exporting a mature form of an antimicrobial peptide known as mutacin III, first identified in Streptococcus mutans UA787 isolated from a caries-active white female patient in the late 1980s (4). Mutacin III is effective against a wide range of Gram-positive bacteria implicated in dental caries, e.g. other strains of Streptococcus mutans and Actinomyces naeslundii, while Gram-negative bacteria are resistant to inhibition (5).



In one investigation of the activity of mutacin-related lantibiotic gallidermin it became clear that lantibiotics are more effective in preventing biofilm formation rather than in exterminating microorganisms already embedded in biofilms (6). To reflect this, our device could be used to transform E. coli cells and employed as an anti-cariogenic strategy in replacement therapy (Fig. 1). Such a novel bacterial strain would demonstrate features of a successful effector strain as it would not cause disease by itself and because it could displace the host pathogenic bacteria. Importantly, there are very few existing examples of lantibiotic resistance compared with antibiotics and only one mechanism of resistance to mutacin III, known as CprRK in Clostridium difficile, has been established (7). Moreover, the fact that a closely related lantibiotic nisin has been shown to exhibit low in vivo toxicity levels (8) and has been widely used as food preservative from as early as mid 1940s (9) further encourages the prospect of considering the employment of mutacin III as an anti-cariogenic agent.


Fig. 1. Simplified representation of the application of the mutacin III biosynthetic device in replacement therapy



The information on the design of the mutacin III biosynthetic device can be found ''here''





LanA

In addition to the proposed device, we created a separate Registry entry for lanA, a structural mutacin 1140 propeptide gene which could be used as the first step towards the assembly of an alternative bacteriocin-producing device.



References


  1. Gil-Montoya JA, de Mello ALF, Barrios R, Gonzalez-Moles MA, Bravo M. Oral health in the elderly patient and its impact on general well-being: a nonsystematic review. Clin Interv Aging. 2015;10:461–7.
  2. Rouxel P, Tsakos G, Chandola T, Watt RG. Oral Health-A Neglected Aspect of Subjective Well-Being in Later Life. J Gerontol B Psychol Sci Soc Sci. 2016 Mar 12.
  3. Anderson MH. Changing paradigms in caries management. Curr Opin Dent. 1992 Mar;2:157–62.
  4. Qi F, Chen P, Caufield PW. Purification of mutacin III from group III Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl Environ Microbiol. 1999 Sep;65(9):3880–7
  5. Hillman JD, Johnson KP, Yaphe BI. Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun. 1984 Apr;44(1):141–4.
  6. Saising J, Dube L, Ziebandt A-K, Voravuthikunchai SP, Nega M, Gotz F. Activity of Gallidermin on Staphylococcus aureus and Staphylococcus epidermidis Biofilms. Antimicrob Agents Chemother. 2012 Nov 1;56(11):5804–10.
  7. Draper LA, Cotter PD, Hill C, Ross RP. Lantibiotic Resistance. Microbiol Mol Biol Rev. 2015 Jun;79(2):171–91.
  8. Hagiwara A, Imai N, Nakashima H, Toda Y, Kawabe M, Furukawa F, et al. A 90-day oral toxicity study of nisin A, an anti-microbial peptide derived from Lactococcus lactis subsp. lactis, in F344 rats. Food Chem Toxicol. 2010 Aug;48(8-9):2421–8.
  9. Delves-Broughton J. Nisin and its application as a food preservative. Int J Dairy Technol. 1990 Aug;43(3):73–6.